Articles by Emily Menendez
An exploratory analysis revealed a strong OS advantage associated with a PD-L1 combined positive score higher than 1.
The combination of ADT and radiotherapy can provide quick benefits in patients with intermediate- or high-risk localized PCa.
Apalutamide can boost rPFS and OS in patients with mHSPC when diagnosed via conventional imaging.
At the time of a pre-specified interim analysis, significant improvements in EFS and OS were seen.
177Lu vipivotide tetraxetan is the only PSMA-targeted agent to significantly improve rPFS with a tolerable safety profile.
Surgical resection of the primary tumor can provide survival benefits in certain patients with metastatic UTUC.
Previous research has shown that BLC can provide improved detection rates, mainly for high-risk disease and invasive tumors.
Patients with mRCC on Medicare have better survival rates compared with patients on Medicaid or with no insurance.
Germline genetic testing is underused for patients with prostate cancer, despite many being eligible for the procedure.
Enzalutamide with [177Lu]Lu-PSMA-617 improved OS and HRQOL, along with PSA PFS.
A recent proof-of-concept study has further evaluated the efficacy of PSMA-guided MDT for oligometastatic RCC.
COSMIC-021 began in 2017 to analyze the effects of cabozantinib alone or with atezolizumab for advanced solid tumors.
This newly developed assay can assess the genomic profile of ctDNA in patients with advanced UC.
The combination therapy provided similar survival rates and toxicity in an older patient population.
The combination demonstrated a manageable safety profile with evidence of EZH2 pharmacodynamic inhibition and OR.
Preliminary results of the study showed promising efficacy and safety with neoadjuvant treatment with DV plus toripalimab.
EV with erdafitinib is a feasible combination with the ability to provide promising antitumor activity in mUC.
Previous data from the phase II CALYPSO study has demonstrated the efficacy of durvalumab in combination with savolitinib.
A long-term efficacy benefit was seen with nivolumab plus cabozantinib over sunitinib, with no new safety signals.
The EPIC-A trial has demonstrated the efficacy and safety of cemiplimab combined with platinum-based chemotherapy for la/mPC.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.